Centre de Ressources

Cette section contient des recherches internationales et peut faire référence à des indications qui ne sont pas approuvées dans toutes les régions. Veuillez consulter les indications approuvées localement avant utilisation.

Filtrer par:

Rechercher
  • Communiqués de presse

Pulsenmore strategic agreement with Clalit for at-home follicular monitoring

Pulsenmore FC at-home ultrasound for follicular monitoring

Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month

En savoir plus
  • Newsletters

January 2026 Newsletter

We’re excited to share a few key updates from Pulsenmore as we continue to expand our impact in maternal-fetal care. FDA authorization, and what it unlocks Receiving FDA De Novo

En savoir plus
  • Actualités

We’re honored to have Prof. Alfred Abuhamad, a global leader in maternal-fetal medicine, on the Pulsenmore advisory board.

Pulsenmore introduces a transformative model for prenatal care - extending ultrasound access beyond the clinic and redefining how we reach and monitor expectant mothers.
En savoir plus
  • Actualités, Communiqués de presse

FDA De Novo marketing authorization

RAMAT GAN, Israel, Nov. 3, 2025 /PRNewswire/ -- Pulsenmore Ltd. (TASE: PULS), a pioneer in home ultrasound solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted
En savoir plus
  • Actualités

We are thrilled to announce our collaboration with ARC innovation

We are thrilled to announce our collaboration with ARC Innovation and Dr. Avi (Abraham) Tsur, MD),
En savoir plus
  • Actualités

The case of Shkedia Zeff Luzzatto

Feeling your baby move is one of the most reassuring signs during pregnancy - but what happens when an anterior placenta makes that much harder?
En savoir plus

Actualités

Nous vous invitons à vous tenir au courant des dernières nouvelles en vous inscrivant à notre newsletter trimestrielle

S’abonner

FAQ

Foire aux questions